Merck
City of Hope, Imugene Begin Trial of Oncolytic Virus in Advanced Solid Cancers
The partners will see if the oncolytic virus CF33-hNIS, dubbed Vaxinia, can increase PD-L1 tumor expression and make patients responsive to Merck's Keytruda.
Merck Nabs European Approvals for Keytruda in Cervical Cancer, Biomarker-Defined Solid Tumors
European regulators approved the agent for PD-L1-positive cervical cancer and for five tumor types defined by high microsatellite instability or DNA mismatch repair deficiency.
Merck Q1 Revenues Increase 50 Percent Driven by Keytruda
The firm's checkpoint inhibitor was once again the primary growth driver, as the drugmaker continues to push the blockbuster into earlier-line treatment settings.
PDS Biotechnology Nets $1.2M Through NJ Economic Development Program to Advance Oncology Candidates
The firm sold its net operating loss tax benefits for cash proceeds under the New Jersey Technology Business Tax Certificate Transfer Net Operating Loss program.
UPenn Researchers Enrolling BRCA1/2 Carriers Into Inovio hTERT Cancer Vaccine study
Research into cancer interception tactics still have a long way to go, but studies like that of Inovio's INO 5401 could offer a framework, a prominent cancer researcher suggested at AACR.